Atea Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2021 | FY2020 |
|---|---|---|
| Revenue | $351.4M | $48.6M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $167.2M | $38.0M |
| SG&A Expense | $45.8M | $21.6M |
| Operating Income | $138.4M | $-11.0M |
| Operating Margin | 39.4% | -22.7% |
| Interest Expense | — | — |
| Pretax Income | $138.6M | $-10.9M |
| Income Tax Expense | $17.4M | — |
| Net Income | $121.2M | $-10.9M |
| Net Margin | 34.5% | -22.5% |
| EPS (Basic) | $1.46 | $-0.13 |
| EPS (Diluted) | $1.37 | $-0.13 |
| Shares Outstanding (Basic) | 82.8M | 86.4M |
| Shares Outstanding (Diluted) | 88.2M | 86.4M |
| Dividends Per Share | — | — |